VesiX cetylpyridinium chloride is rapidly bactericidal and reduces uropathogenic Escherichia coli bladder epithelial cell invasion in vitro .

Autor:	Sawant NV; Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA., Chang SS; Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA., Pandit KA; Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA., Khekare P; Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA., Warner WR; US BioPharma LLC, Punta Gorda, Florida, USA., Zimmern PE; Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA., De Nisco NJ; Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA.; Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jazyk:	angličtina
Zdroj:	Microbiology spectrum [Microbiol Spectr] 2024 Mar 05; Vol. 12 (3), pp. e0271223. Date of Electronic Publication: 2024 Jan 19.
DOI:	10.1128/spectrum.02712-23
Abstrakt:	Management of urinary tract infection (UTI) in postmenopausal women can be challenging. The recent rise in resistance to most of the available oral antibiotic options together with high recurrence rate in postmenopausal women has further complicated treatment of UTI. As such, intravesical instillations of antibiotics like gentamicin are being investigated as an alternative to oral antibiotic therapies. This study evaluates the efficacy of the candidate intravesical therapeutic VesiX, a solution containing the cationic detergent Cetylpyridinium chloride, against a broad range of uropathogenic bacterial species clinically isolated from postmenopausal women with recurrent UTI (rUTI). We also evaluate the cytotoxicity of VesiX against cultured bladder epithelial cells and find that low concentrations of 0.0063% and 0.0125% provide significant bactericidal effect toward diverse bacterial species including uropathogenic Escherichia coli (UPEC), Klebsiella pneumoniae , Enterococcus faecalis , Pseudomonas aeruginosa , and Proteus mirabilis while minimizing cytotoxic effects against cultured 5637 bladder epithelial cells. Lastly, to begin to evaluate the potential utility of using VesiX in combination therapy with existing intravesical therapies for rUTI, we investigate the combined effects of VesiX and the intravesical antibiotic gentamicin. We find that VesiX and gentamicin are not antagonistic and are able to reduce levels of intracellular UPEC in cultured bladder epithelial cells. Importance: When urinary tract infections (UTIs), which affect over 50% of women, become resistant to available antibiotic therapies dangerous complications like kidney infection and lethal sepsis can occur. New therapeutic paradigms are needed to expand our arsenal against these difficult to manage infections. Our study investigates VesiX, a Cetylpyridinium chloride (CPC)-based therapeutic, as a candidate broad-spectrum antimicrobial agent for use in bladder instillation therapy for antibiotic-resistant UTI. CPC is a cationic surfactant that is FDA-approved for use in mouthwashes and is used as a food additive but has not been extensively evaluated as a UTI therapeutic. Our study is the first to investigate its rapid bactericidal kinetics against diverse uropathogenic bacterial species isolated from postmenopausal women with recurrent UTI and host cytotoxicity. We also report that together with the FDA-approved bladder-instillation agent gentamicin, VesiX was able to significantly reduce intracellular populations of uropathogenic bacteria in cultured bladder epithelial cells. Competing Interests: W. Randolph Warner discloses an affiliation with US BioPharma.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu